SCHEMBL6994691

SCHEMBL6994691

CC(C)(C)OC(=O)N1CC(C(=O)Cl)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.56
HPGD P15428 1/20 0.50
USP2 O75604 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46
RECQL P46063 1/20 0.44
EPHX1 P07099 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
EPHX2 P34913 1/20 0.42
KDM4E B2RXH2 1/20 0.41
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2977895 0.87 NR1H2 (0.64) NR1H2HPGDUSP2SMN1; SMN2MEN1
SCHEMBL2988189 0.86 NR1H2 (0.50) NR1H2HPGDUSP2SMN1; SMN2MEN1
SCHEMBL19586850 0.86 HPGD (0.60) NR1H2HPGDUSP2SMN1; SMN2MEN1
SCHEMBL17643712 0.86 HPGD (0.60) NR1H2HPGDUSP2SMN1; SMN2MEN1
SCHEMBL16632768 0.84 NR1H2 (0.54) NR1H2HPGDUSP2SMN1; SMN2MEN1
SCHEMBL1849876 0.83 MEN1 (0.63) NR1H2HPGDUSP2SMN1; SMN2MEN1
SCHEMBL14478715 0.83 NR1H2 (0.54) NR1H2HPGDUSP2SMN1; SMN2MEN1
SCHEMBL89062 0.83 NR1H2 (0.54) NR1H2HPGDUSP2SMN1; SMN2MEN1
SCHEMBL20220628 0.83 NR1H2 (0.54) NR1H2HPGDUSP2SMN1; SMN2MEN1
SCHEMBL57263 0.83 NR1H2 (0.54) NR1H2HPGDUSP2SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688741-A1 COMPOUNDS FOR TREATING FIBROTIC DISEASES Meta-Immune, Inc. (KR) 2026-02-11 EP disclosed
US-20250380697-A1 ISOXAZOLINE DERIVATIVE COMPOUND AND INSECTICIDAL COMPOSITION COMPRISING SAME KYUNG NONG CORPORATION (KR) 2025-12-18 US disclosed
WO-2024249867-A1 COMPOUNDS FOR TREATING FIBROTIC DISEASES AM SCIENCES (KR) 2024-12-05 WO disclosed
EP-4110781-B1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2024-07-31 EP disclosed
US-20240024488-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-01-25 US disclosed
US-20240024488-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-01-25 US disclosed
WO-2024005548-A1 ISOXAZOLINE DERIVATIVE COMPOUND AND INSECTICIDAL COMPOSITION COMPRISING SAME 주식회사 경농 2024-01-04 WO disclosed
US-20230278995-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-09-07 US disclosed
US-20230271955-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-31 US disclosed
US-20230271955-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-31 US disclosed
US-20150105366-A1 METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt JANSSEN PHARMACEUTICA NV (BE) 2015-04-16 US disclosed
US-20140221339-A1 Heterocyclic Derivative and Pharmaceutical Drug NIPPON SHINYAKU CO., LTD. (JP) 2014-08-07 US disclosed
EP-2746265-A1 HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL DRUG Nippon Shinyaku Co., Ltd. (JP) 2014-06-25 EP disclosed
CN-103857657-A Heterocyclic derivative and pharmaceutical drug NIPPON SHINYAKU CO LTD 2014-06-11 CN disclosed
EP-0874809-B1 CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2003-08-27 EP disclosed
US-6239175-B1 Carbamoyloxy derivatives of mutiline and their use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2001-05-29 US disclosed
US-6020368-A MICROBIOCIDES HINKS JEREMY DAVID (US) 2000-02-01 US disclosed
CN-1214039-A Carbamoyloxy derivatives of mutiline and their use as antibacterials SMITHKLINE BEECHAM PLC (GB) 1999-04-14 CN disclosed
EP-0874809-A1 CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 1998-11-04 EP disclosed
WO-1997025309-A1 CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 1997-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278995-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC6, HDAC1, HDAC11 NR1H2 1027/4885HPGD 844/4885USP2 2395/4885
US-20140221339-A1 Heterocyclic Derivative and Pharmaceutical Drug PTGES, PTGER1, PTGS1 NR1H2 1227/4885HPGD 13/4885USP2 1912/4885
US-20150105366-A1 METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt RORC, RORA, RORB NR1H2 5/4885HPGD 2168/4885USP2 3993/4885
US-20230271955-A1 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC6, HDAC1, HDAC2 NR1H2 1385/4885HPGD 1054/4885USP2 2042/4885
US-20250380697-A1 ISOXAZOLINE DERIVATIVE COMPOUND AND INSECTICIDAL COMPOSITION COMPRISING SAME VIP, CASP7, CYP4X1 NR1H2 770/4885HPGD 1764/4885USP2 3763/4885
US-20240024488-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB NR1H2 1847/4885HPGD 3705/4885USP2 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.